Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
World J Gastroenterol. 2011 May 14;17(18):2288-301. doi: 10.3748/wjg.v17.i18.2288.

Silybin and the liver: from basic research to clinical practice.

Author information

  • 1Gastroenterology School-Interuniversity Research Centre on Foods, Nutrition and Gastrointestinal Tract (CIRANAD), 2nd University of Naples, 80131 Naples, Italy. carmelina.loguercio@unina2.it

Abstract

Herbal products are increasingly used, mainly in chronic liver disease. Extracts of milk thistle, Silymarin and silybin, are the most prescribed natural compounds, with different indications, but with no definitive results in terms of clinical efficacy. This review analyzes the available studies on the effects of the purified product silybin, both as a free and a conjugated molecule, on liver cells or on experimentally induced liver damage, and in patients with liver disease. We searched PUBMED for articles pertaining to the in vitro and in vivo effects of silybin, its antifibrotic, anti-inflammatory, and antioxidant properties, as well as its metabolic effects, combined with the authors' own knowledge of the literature. Results indicate that the bioavailability of silybin phytosome is higher than that of silymarin and is less influenced by liver damage; silybin does not show significant interactions with other drugs and at doses < 10 g/d has no significant side effects. Experimental studies have clearly demonstrated the antifibrotic, antioxidant and metabolic effects of silybin; previous human studies were insufficient for confirming the clinical efficacy in chronic liver disease, while ongoing clinical trials are promising. On the basis of literature data, silybin seems a promising drug for chronic liver disease.

KEYWORDS:

Hepatic fibrosis, Hepatic inflammation, Liver disease, Milk thistle, Radical species, Silymarin

PMID:
21633595
[PubMed - indexed for MEDLINE]
PMCID:
PMC3098397
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Baishideng Publishing Group Co., Limited Icon for PubMed Central
    Loading ...
    Write to the Help Desk